We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Advanced Digital Pathology System Enters Service in the United Kingdom

By LabMedica International staff writers
Posted on 20 Dec 2015
A major British hospital has incorporated an advanced digital pathology system, which is expected to increase diagnostic accuracy as well as streamlining the performance of the pathology department.

Digital pathology takes the traditional pathology workflow—slides and microscopes—and uses scanners and software to digitize slides. More...
With digitized slides, pathologists can examine high-resolution digital pathology workflow images with the aid of precision software tools. Pathologists can review case files with the slide image still in full view, and notes can be linked to specific areas of interest. Images and comments can be shared between healthcare teams with the same ease as sending an email.

Pathologists at University Hospitals Coventry and Warwickshire NHS Trust (United Kingdom) have begun to operate the Omnyx (Pittsburgh, PA, USA) Precision Solution digitalized pathology system. This state-of-the-art technology enables pathologists to accurately grade some types of tumors, including lung, prostate, and bladder tumors. In the first stage of adapting the system, more than 10,000 slides were examined in a study that showed that pathologists were as accurate diagnosing cancer with a computer as they had been with a microscope.

First author Dr. David Snead, professor of pathology at University Hospitals Coventry and Warwickshire NHS Trust, said, “I am delighted that University Hospital, Coventry has led this ground breaking study. This provides even greater evidence that digital pathology really works, and works well. The introduction of digital pathology has fantastic potential benefits for patients. We can expect to be able to read samples more quickly than before, and the big advantage is that we can use the computer to easily manipulate an image or its data. For some patients, this additional information may change how their disease is managed.”

Mamar Gelaye, CEO of Omnyx, said, “Dr. Snead and his team have made a significant contribution to showing the value of digital pathology for both clinicians and patients. We are only at the beginning of harnessing the benefits of digitizing pathology services, and we look forward to working with institutions like University Hospitals Coventry and Warwickshire NHS Trust to achieve even greater progress in delivering more accurate and efficient cancer diagnoses.”

The study was published in the December 6, 2015, online edition of the journal Histopathology.

Related Links:

University Hospitals Coventry and Warwickshire NHS Trust
Omnyx



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.